Please select the option that best describes you:
How do you choose between the different available CAR-T cell therapy products for the treatment of relapsed Ph-negative ALL?
Answer from: Medical Oncologist at Academic Institution
As implied by the question, there are now three (3) CD19 CAR-T cell products approved by the FDA for adults with relapsed/refractory B-ALL: tisagenlecleucel (tisa-cel), brexucabtagene autoleucel (brexu-cel), and obecabtagene autoleucel (obe-cel). They were all approved after single-arm prospective t...
Sign In or Register to read more
Answer from: Medical Oncologist at Academic Institution
Which CAR-T product should be used for any given patient should be a personalized decision, based on the patient's age, comorbidities, and disease burden at the time of treatment. Results from the ZUMA-3 trial of brexucabtagene autoleucel (brexu-cel) showed a CR/CRi rate of 73%, which is comparable ...